Literature DB >> 17217130

High success rate of TB treatment among Bhutanese refugees in Nepal.

T S Bam1, D A Enarson, S G Hinderaker, R S Chapman.   

Abstract

SETTING: Camps for refugees from Bhutan in south-east Nepal.
OBJECTIVES: To evaluate the outcome of treatment of tuberculosis (TB) cases in the refugee camps.
DESIGN: Cohort analysis of results of treatment of cases started on treatment from mid-July 1999 to mid-July 2004. RESULT: A total of 1214 patients with TB were notified in the programme. Among these, 631 (52%) were new smear-positive pulmonary tuberculosis (PTB) cases, 175 (14%) new smear-negative PTB cases, 290 (24%) new extra-pulmonary TB (EPTB) cases and 118 (10%) smear-positive retreatment cases. Treatment success was achieved in 1061 (94%). The proportion of new non-smear-positive cases who died on treatment was significantly higher than the corresponding figure for new smear-positive cases (RR 7.57, 95%CI 3.74-15.32 for new smear-negative and 4.22, 95%CI 2.08-8.55 for EPTB).
CONCLUSION: High cure rates and low bacteriological failure rates can be achieved in refugee settings if there is close coordination and collaboration between the local health agencies and the National Tuberculosis Programme of the host country.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17217130

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Delivering infectious disease interventions to women and children in conflict settings: a systematic reviefw.

Authors:  Sarah Meteke; Marianne Stefopulos; Daina Als; Michelle Gaffey; Mahdis Kamali; Fahad J Siddiqui; Mariella Munyuzangabo; Reena P Jain; Shailja Shah; Amruta Radhakrishnan; Anushka Ataullahjan; Zulfiqar A Bhutta
Journal:  BMJ Glob Health       Date:  2020-04

2.  A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.

Authors:  D B Cohen; J Meghji; S B Squire
Journal:  Int J Tuberc Lung Dis       Date:  2018-10-01       Impact factor: 2.373

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.